Lakewood-Amedex Biotherapeutics Inc.
LABT· Nasdaq
LABTLakewood-Amedex Biotherapeutics Inc.
Filed Aug 14, 2026 · 10-Q · 45 days after period end · 0001213900-26-089380
| Metric | Q2 2026 | Q2 2025 |
|---|---|---|
| Net Income | -$3.77M | -$655.94K |
| EPS Diluted | -$2.75 | -$1.66 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
ended Jun 30, 2026 · filed Aug 14, 2026 · 45 d after period end
Lakewood-Amedex Biotherapeutics Inc. · CIK 2079272 · Engraved from SEC EDGAR
